Cochrane · systematic review · CD010062
Sulthiame monotherapy for epilepsy
Milburn-McNulty, P, Panebianco, M, Marson, AG · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
23
current version
GRADE rated
18
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 5 · 21.7%Very low 0 · 0%Low 18 · 78.3%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlySulthiame compared to placebo for epilepsy
Population: participants with epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Treatment withdrawal Sulthiame vs placebo | no estimate extracted | 2 studies · 100 participants | Ungraded |
Seizure freedom Sulthiame vs placebo | no estimate extracted | 2 studies · 100 participants | Ungraded |
All adverse effects Sulthiame vs placebo | no estimate extracted | 2 studies · 100 participants | Ungraded |
Sulthiame compared with levetiracetam for epilepsy
Population: participants with epilepsy (BECTS)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Treatment withdrawal Sulthiame vs levetiracetam | RR 0.32 [0.1, 1.03] | 1 study · 43 participants | Low Downgraded: risk of bias, imprecision |
Seizure freedom Sulthiame vs levetiracetam | RR 1.12 [0.88, 1.44] | 1 study · 43 participants | Low Downgraded: risk of bias, imprecision |
Adverse effects (general symptoms) Sulthiame vs levetiracetam | RR 1.08 [0.76, 1.54] | 1 study · 43 participants | Low Downgraded: risk of bias, imprecision |
Adverse effects (central nervous system) Sulthiame vs levetiracetam | RR 1.17 [0.77, 1.79] | 1 study · 43 participants | Low Downgraded: risk of bias, imprecision |
Adverse effects (behaviour) Sulthiame vs levetiracetam | RR 0.95 [0.59, 1.55] | 1 study · 43 participants | Low Downgraded: risk of bias, imprecision |
Adverse effects (airways) Sulthiame vs levetiracetam | RR 2.67 [1.17, 6.12] | 1 study · 43 participants | Low Downgraded: risk of bias, imprecision |
Adverse effects (cardiac) Sulthiame vs levetiracetam | RR 2.87 [0.12, 66.75] | 1 study · 43 participants | Low Downgraded: risk of bias, imprecision |
Adverse effects (gastrointestinal) Sulthiame vs levetiracetam | RR 0.76 [0.37, 1.56] | 1 study · 43 participants | Low Downgraded: risk of bias, imprecision |
Adverse effects (bones and muscles) Sulthiame vs levetiracetam | RR 0.95 [0.27, 3.33] | 1 study · 43 participants | Low Downgraded: risk of bias, imprecision |
Adverse effects (others) Sulthiame vs levetiracetam | RR 1.19 [0.37, 3.85] | 1 study · 43 participants | Low Downgraded: risk of bias, imprecision |
Sulthiame compared with phenytoin for epilepsy
Population: participants with epilepsy (GTCS)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Treatment withdrawal Sulthiame vs phenytoin | no estimate extracted | 1 study · 146 participants | Ungraded |
Seizure freedom Sulthiame vs phenytoin | no estimate extracted | 1 study · 146 participants | Ungraded |
All adverse effects Sulthiame vs phenytoin | RR 1.05 [0.54, 2.07] | 1 study · 146 participants | Low Downgraded: risk of bias, imprecision |
Paraesthesia Sulthiame vs phenytoin | RR 8.32 [0.51, 135.82] | 1 study · 146 participants | Low Downgraded: risk of bias, imprecision |
Dizziness Sulthiame vs phenytoin | RR 3.16 [0.18, 55.62] | 1 study · 146 participants | Low Downgraded: risk of bias, imprecision |
Headache Sulthiame vs phenytoin | RR 1.43 [0.07, 29.15] | 1 study · 146 participants | Low Downgraded: risk of bias, imprecision |
Anorexia Sulthiame vs phenytoin | RR 0.42 [0.07, 2.41] | 1 study · 146 participants | Low Downgraded: risk of bias, imprecision |
Rash Sulthiame vs phenytoin | RR 0.28 [0.02, 4.36] | 1 study · 146 participants | Low Downgraded: risk of bias, imprecision |
Gingival hyperplasia Sulthiame vs phenytoin | RR 0.03 [0, 0.58] | 1 study · 146 participants | Low Downgraded: risk of bias, imprecision |
Other Sulthiame vs phenytoin | RR 1.4 [0.17, 11.59] | 1 study · 146 participants | Low Downgraded: risk of bias, imprecision |
Summary of findings
Population: participants with epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All adverse effects—sulthiame versus placebo (benign epilepsy of childhood with centrotemporal spikes) Six months | no estimate extracted | 66 studies · 66 participants | Low |
All adverse effects—sulthiame versus phenytoin (generalised tonic‐clonic seizures) Six months | RR 1.05 [0.54, 2.07] | 146 studies · 146 participants | Very low |
Paraesthesia—sulthiame versus phenytoin (generalised tonic‐clonic seizures) Six months | RR 8.32 [0.51, 135.82] | 146 studies · 146 participants | Very low |
Dizziness—sulthiame versus phenytoin Six months | RR 3.16 [0.18, 55.62] | 146 studies · 146 participants | Very low |
Headache—sulthiame versus phenytoin (generalised tonic‐clonic seizures) Six months | RR 1.43 [0.07, 2.41] | 146 studies · 146 participants | Very low |
Anorexia—sulthiame versus phenytoin (generalised tonic‐clonic seizures) Six months | RR 0.42 [0.07, 2.41] | 146 studies · 146 participants | Very low |
Rash—sulthiame versus phenytoin (generalised tonic‐clonic seizures) Six months | RR 0.28 [0.02, 4.36] | 146 studies · 146 participants | Very low |
Gingival hyperplasia—sulthiame versus phenytoin (generalised tonic‐clonic seizures) Six months | RR 0.03 [0, 0.58] | 146 studies · 146 participants | Very low |
Other—sulthiame versus phenytoin (generalised tonic‐clonic seizures) Six months | RR 1.4 [0.17, 11.59] | 146 studies · 146 participants | Very low |